Company Filing History:
Years Active: 2009
Title: Jürgen Götz: Innovator in Neurodegenerative Disease Research
Introduction
Jürgen Götz is a prominent inventor based in Zurich, Switzerland. He has made significant contributions to the field of neurodegenerative diseases, particularly in understanding Alzheimer's disease. His innovative work has led to the development of methods that could potentially aid in the identification and testing of therapies for these debilitating conditions.
Latest Patents
Jürgen Götz holds a patent titled "Inducing neurofibrillary tangles in transgenic mice expressing a mutant tau protein." This invention discloses a method and an in-vivo assay system useful for identifying and testing modulating agents, as well as validating therapies for neurodegenerative diseases associated with neurofibrillary tangles. The patent is based on the surprising finding that the injection of β-amyloid Aβ fibrils into the brains of P301L mutant tau transgenic mice resulted in a significant increase in the numbers and accelerated production of neurofibrillary tangles, particularly within the amygdala. These tangles appeared as early as 18 days after the Aβ injections and exhibited features characteristic of neurofibrillary tangles found in various human neurodegenerative diseases, especially Alzheimer's disease.
Career Highlights
Jürgen Götz is affiliated with Universität Zürich, where he continues to advance research in neurodegenerative diseases. His work has garnered attention for its potential implications in understanding and treating Alzheimer's disease.
Collaborations
Jürgen Götz has collaborated with notable researchers in his field, including Roger Nitsch and Feng Chen. These collaborations have further enriched his research and contributed to the advancement of knowledge in neurodegenerative disease mechanisms.
Conclusion
Jürgen Götz is a key figure in the research of neurodegenerative diseases, with a focus on Alzheimer's disease. His innovative patent and ongoing work at Universität Zürich highlight his commitment to advancing therapeutic strategies for these challenging conditions.